Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV‐Infected Adults – Canadian Consensus Guidelines | Zendy

Anita Rachlis | Zendy; Jonathan B. Angel | Zendy; Marianne Harris | Zendy; Stephen D. Shafran | Zendy; Rachel Therrien | Zendy; Cécile Tremblay | Zendy; Mark A. Wainberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV‐Infected Adults – Canadian Consensus Guidelines

Author(s) -

Anita Rachlis,

Jonathan B. Angel,

Marianne Harris,

Stephen D. Shafran,

Rachel Therrien,

Cécile Tremblay,

Mark A. Wainberg

Publication year - 2009

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2009/940745

Subject(s) - raltegravir , human immunodeficiency virus (hiv) , medicine , virology , antiretroviral therapy , intensive care medicine , viral load

A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress(R), Merck Frosst Canada Inc) in HIV-infected adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research